Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Preoperative Chemoradiotherapy for Gastrointestinal Cancer
share announcement

Preoperative Chemoradiotherapy for Gastrointestinal Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 October 2024 | Viewed by 2196

Special Issue Editors

Prof. Dr. Kazuo Koyanagi

E-Mail Website
Guest Editor
Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan
Interests: esophageal cancer; esophagogastric junction cancer; gastric cancer; minimally invasive esophagectomy; robot-assisted minimally invasive esophagectomy
Dr. Yoshiaki Shoji

E-Mail Website
Guest Editor
Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan
Interests: esophageal cancer; esophagogastric junction cancer; gastric cancer; minimally invasive esophagectomy; robot-assisted minimally invasive esophagectomy

Special Issue Information

Dear Colleagues,

Multidisciplinary treatment including perioperative therapy and surgery have been widely accepted worldwide to improve patient outcomes for locally advanced gastrointestinal cancers. Improvement of short- and long-course preoperative chemoradiotherapy has led to increased treatment responses and R0 resection rate, thus contributing to prolonged patient survival. However, depending on tumor site, the safety of preoperative chemoradiotherapy, and the efficacy against induction/neoadjuvant chemotherapy, have been questioned. Regarding esophageal cancer, preoperative chemoradiotherapy consisting of cisplatin, 5-fluorouracil, and an irradiation dose of 40.4Gy have led to increased pathological complete response rates; however, this combination could not demonstrate overall survival benefits when compared to conventional cisplatin + 5-fluorouracil therapy, possibly due to adverse events caused by chemoradiotherapy in the JCOG1109(NExT) study. Increased attention has been paid to the safety of preoperative radiotherapy, as well as the development of an effective chemotherapeutic regimen when combined with radiation treatment.

The purpose of this Special Issue is to clarify the current status and the therapeutic development of preoperative chemoradiotherapy, thereby contributing to increased outcomes for patients with gastrointestinal diseases. This Special Issue welcomes clinical studies on therapeutic approaches, translational research for treatment development, reviews, and other articles related to preoperative chemoradiotherapy for gastrointestinal cancer.

Prof. Dr. Kazuo Koyanagi
Dr. Yoshiaki Shoji
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • preoperative therapy
  • perioperative therapy
  • chemoradiotherapy
  • neoadjuvant therapy
  • induction therapy
  • conversion surgery
  • gastrointestinal cancer

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1179 KiB  
Article
Identifying the Trends of Urinary microRNAs within Extracellular Vesicles for Esophageal Cancer
by Kazuhiko Hisaoka, Satoru Matsuda, Kodai Minoura, Hiroki Yamaguchi, Yuki Ichikawa, Mika Mizunuma, Ryota Kobayashi, Yosuke Morimoto, Masashi Takeuchi, Kazumasa Fukuda, Rieko Nakamura, Shutaro Hori, Taigi Yamazaki, Takehiko Sambe, Hirofumi Kawakubo and Yuko Kitagawa
Cancers 2024, 16(9), 1698; https://doi.org/10.3390/cancers16091698 - 27 Apr 2024
Viewed by 219
Abstract
Background: The advancement of multidisciplinary treatment has increased the need to develop tests to monitor tumor burden during treatment. We herein analyzed urinary microRNAs within extracellular vesicles from patients with esophageal squamous cell carcinoma (ESCC) and normal individuals using a microarray. Methods: [...] Read more.
Background: The advancement of multidisciplinary treatment has increased the need to develop tests to monitor tumor burden during treatment. We herein analyzed urinary microRNAs within extracellular vesicles from patients with esophageal squamous cell carcinoma (ESCC) and normal individuals using a microarray. Methods: Patients with advanced ESCC who underwent esophagectomy (A), endoscopic submucosal resection (ESD) (B), and healthy donors (C) were included. Based on microRNA expression among the groups (Analysis 1), microRNAs with significant differences between groups A and C were selected (Analysis 2). Of these candidates, microRNAs in which the change between A and C was consistent with the change between B and C were selected for downstream analysis (Analysis 3). Finally, microRNA expression was validated in patients with recurrence from A (exploratory analysis). Results: For analysis 1, 205 microRNAs were selected. For Analyses 2 and 3, the changes in 18 microRNAs were consistent with changes in tumor burden as determined by clinical imaging and pathological findings. The AUC for the detection of ESCC using 18 microRNAs was 0.72. In exploratory analysis, three of eighteen microRNAs exhibited a concordant trend with recurrence. Conclusions: The current study identified the urinary microRNAs which were significantly expressed in ESCC patients. Validation study is warranted to evaluate whether these microRNAs could reflect tumor burden during multidisciplinary treatment for ESCC. Full article
(This article belongs to the Special Issue Preoperative Chemoradiotherapy for Gastrointestinal Cancer)
►▼ Show Figures

Figure 1

13 pages, 1268 KiB  
Article
Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
by Yuki Hirata, Yi-Ju Chiang, Jeannelyn S. Estrella, Prajnan Das, Bruce D. Minsky, Mariela Blum Murphy, Jaffer A. Ajani, Paul Mansfield, Brian D. Badgwell and Naruhiko Ikoma
Cancers 2023, 15(21), 5137; https://doi.org/10.3390/cancers15215137 - 25 Oct 2023
Viewed by 961
Abstract
In gastroesophageal junction (GEJ) adenocarcinoma cases, a prognosis based on ypTNM staging could be affected by preoperative therapy. Patients with esophageal adenocarcinoma and gastric adenocarcinoma who underwent preoperative therapy followed by surgical resection from 2006 through 2017 were identified in the National Cancer [...] Read more.
In gastroesophageal junction (GEJ) adenocarcinoma cases, a prognosis based on ypTNM staging could be affected by preoperative therapy. Patients with esophageal adenocarcinoma and gastric adenocarcinoma who underwent preoperative therapy followed by surgical resection from 2006 through 2017 were identified in the National Cancer Database. To enable stage-by-stage OS comparisons, tumors were classified into four gross ypTNM groups: ypT1/2, N-negative; ypT1/2, N-positive; ypT3/4, N-negative; and ypT3/4, N-positive. Prognostic factors were examined, and an OS prediction nomogram was developed for patients with abdominal/lower esophageal and gastric cardia adenocarcinoma, representing GEJ cancers. We examined 25,463 patient records. When compared by gross ypTNM group, the abdominal/lower esophageal and gastric cardia adenocarcinoma groups had similar OS rates, differing from those of other esophageal or gastric cancers. Cox regression analysis of patients with GEJ cancers showed that preoperative chemoradiotherapy was associated with shorter OS than preoperative chemotherapy after adjustment for the ypTNM group (hazard ratio 1.31, 95% CI 1.24–1.39, p < 0.001), likely owing to downstaging effects. The nomogram had a concordance index of 0.833 and a time-dependent area under the curve of 0.669. OS prediction in GEJ adenocarcinoma cases should include preoperative therapy regimens. Our OS prediction nomogram provided reasonable OS prediction for patients with GEJ adenocarcinoma, and future validation is needed. Full article
(This article belongs to the Special Issue Preoperative Chemoradiotherapy for Gastrointestinal Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 269 KiB  
Review
Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review
by Yutaka Endo, Minoru Kitago and Yuko Kitagawa
Cancers 2024, 16(9), 1632; https://doi.org/10.3390/cancers16091632 - 24 Apr 2024
Viewed by 248
Abstract
Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline resectable PC, offering improved resection rates and enabling early intervention and patient selection. Several retrospective studies [...] Read more.
Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline resectable PC, offering improved resection rates and enabling early intervention and patient selection. Several retrospective studies have validated its efficacy. However, previous studies have lacked intention-to-treat analyses and appropriate resectability classifications. Randomized comparative trials may help to enhance the clinical applicability of evidence. Therefore, after searching the MEDLINE database, this scoping review presents a comprehensive summary of the evidence from published (n = 14) and ongoing (n = 12) randomized Phase II and III trials. Diverse regimens and their outcomes were explored for both resectable and borderline resectable PC. While some trials have supported the efficacy of NAT, others have demonstrated no clear survival benefits for patients with resectable PC. The utility of NAT has been confirmed in patients with borderline resectable PC, but the optimal regimens remain debatable. Ongoing trials are investigating novel regimens, including immunotherapy, thereby highlighting the dynamic landscape of PC treatment. Studies should focus on biomarker identification, which may enable precision in oncology. Future endeavors aim to refine treatment strategies, guided by precision oncology. Full article
(This article belongs to the Special Issue Preoperative Chemoradiotherapy for Gastrointestinal Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop